Lingohr Asset Management GmbH Sells 6,363 Shares of Hologic, Inc. (NASDAQ:HOLX)

Lingohr Asset Management GmbH trimmed its position in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 65.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 3,288 shares of the medical equipment provider's stock after selling 6,363 shares during the period. Lingohr Asset Management GmbH's holdings in Hologic were worth $238,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. FMR LLC increased its position in Hologic by 64.0% during the 3rd quarter. FMR LLC now owns 5,572,545 shares of the medical equipment provider's stock valued at $453,940,000 after purchasing an additional 2,174,093 shares during the period. Boston Partners boosted its stake in shares of Hologic by 81.0% during the 4th quarter. Boston Partners now owns 3,580,519 shares of the medical equipment provider's stock valued at $257,959,000 after purchasing an additional 1,602,463 shares in the last quarter. Nordea Investment Management AB boosted its stake in shares of Hologic by 32.7% during the 4th quarter. Nordea Investment Management AB now owns 2,213,607 shares of the medical equipment provider's stock valued at $159,911,000 after purchasing an additional 544,889 shares in the last quarter. Raymond James Financial Inc. purchased a new position in shares of Hologic during the fourth quarter valued at about $27,007,000. Finally, Swedbank AB raised its stake in Hologic by 18.8% in the third quarter. Swedbank AB now owns 1,937,002 shares of the medical equipment provider's stock worth $157,788,000 after buying an additional 306,562 shares in the last quarter. 94.73% of the stock is currently owned by hedge funds and other institutional investors.

Remove Ads

Analysts Set New Price Targets

A number of research analysts have recently commented on HOLX shares. Argus cut Hologic from a "buy" rating to a "hold" rating in a research note on Monday, March 3rd. Evercore ISI decreased their target price on shares of Hologic from $76.00 to $73.00 and set an "in-line" rating for the company in a research note on Thursday, February 6th. BNP Paribas upgraded shares of Hologic to a "strong-buy" rating in a report on Tuesday, December 10th. Leerink Partners downgraded Hologic from an "outperform" rating to a "market perform" rating and cut their price target for the stock from $80.00 to $75.00 in a research note on Thursday, February 6th. Finally, Wolfe Research assumed coverage on Hologic in a research note on Friday, December 13th. They set a "peer perform" rating for the company. Eleven analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average target price of $84.62.

Hologic Stock Performance

NASDAQ HOLX traded up $0.42 during trading hours on Monday, hitting $61.89. The company's stock had a trading volume of 2,689,974 shares, compared to its average volume of 1,754,748. Hologic, Inc. has a 12 month low of $60.34 and a 12 month high of $84.67. The company's 50 day simple moving average is $65.89 and its two-hundred day simple moving average is $73.81. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.49 and a quick ratio of 2.78. The company has a market cap of $13.89 billion, a P/E ratio of 19.52, a price-to-earnings-growth ratio of 2.14 and a beta of 0.97.

Hologic (NASDAQ:HOLX - Get Free Report) last announced its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. As a group, sell-side analysts expect that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.